Christoph Uleer

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Gϋnter von Minckwitz, Andreas du Bois, Marcus Schmidt et al. · Journal of Clinical Oncology · 2009 · 689 citations

Medicine, Oncology, Pharmacotherapy +17

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Ulrike Nitz, Oleg Gluz, Michael Clemens et al. · Journal of Clinical Oncology · 2019 · 147 citations

Medicine, Oncology, Pharmacotherapy +16

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Peter A. Fasching, Theresa Link, Jan Hauke et al. · Annals of Oncology · 2020 · 144 citations · Full text

Medicine, Cancer Biology, Oncology +17